We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
CTI BioPharma Corporation | NASDAQ:CTIC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.09 | 10.01 | 8.64 | 0 | 01:00:00 |
|
||||
|
|
|
|
|
|
|
|
|
|
Delaware
|
|
001-12465
|
|
91-1533912
|
(State or other jurisdiction
of incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
|
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Name
|
Title
|
Option Grant (in shares)
(1)
|
Adam R. Craig, M.D., Ph.D.
|
President, Chief Executive Officer
|
600,000
(2)
|
Bruce Seeley
|
Chief Operating Officer
|
125,000
(3)
|
David H. Kirske
|
Chief Financial Officer
|
125,000
(3)
|
(1)
|
The stock options granted to each of the executives set forth in the table above have an exercise price equal to $1.88, the closing price of the Company’s common shares as reported by The Nasdaq Stock Market LLC on September 18, 2018.
|
(2)
|
The stock option will vest in six equal semi-annual installments over a three-year period commencing on September 18, 2018 subject to continued employment with the Company through the applicable vesting dates, such that the option will be fully vested on September 18, 2021.
|
(3)
|
The award recipient will receive a bonus, payable in non-qualified options for shares of common stock, with each such stock option to vest 100% only upon the Compensation Committee's certification of the European Medicines Agency approval of the Marketing Authorization Application for Pacritinib, assuming that such approval occurs no later than September 30, 2019.
|
Name
|
Title
|
Cash Incentive (% of Annual Salary)
|
Adam R. Craig, M.D., Ph.D.
|
President, Chief Executive Officer
|
55
|
Bruce Seeley
|
Chief Operating Officer
|
20
|
David H. Kirske
|
Chief Financial Officer
|
17.5
|
Audit Committee
|
Nominating and Governance Committee
|
Compensation Committee
|
Michael A. Metzger (Chairman)
|
Reed V. Tuckson, M.D., F.A.C.P. (Chairman)
|
David R. Parkinson, M.D. (Chairman)
|
Reed V. Tuckson, M.D., F.A.C.P
|
Laurent Fischer, M.D.
|
Laurent Fischer, M.D.
|
Frederick W. Telling, Ph.D.
|
|
Matthew D. Perry
|
|
|
|
|
|
|
|
|
|
|
|
|
CTI BIOPHARMA CORP.
|
||
Date: September 21, 2018
|
|
By:
|
|
/s/ David H. Kirske
|
|
|
|
|
David H. Kirske
|
|
|
|
|
Chief Financial Officer
|
|
|
|
|
|
1 Year CTI BioPharma Chart |
1 Month CTI BioPharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions